Gonadorelin
A lab-made copy of the hormone your brain naturally releases to tell your body to make reproductive hormones. When given in short pulses (not continuously), it signals the pituitary gland to release hormones that keep the testes working. Used for fertility treatment, diagnosing hormone problems, and keeping testicular function and sperm production going during testosterone therapy.
Dosage
100-200 mcg subcutaneous 2-3x weekly
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Fertility Preservation
Maintains testicular function and sperm production during TRT.
LH/FSH Stimulation
Pulsatile dosing stimulates natural gonadotropin release.
Testosterone Support
Maintains natural testosterone production by stimulating the pituitary gland.
Mechanism of Action
Gonadorelin is a synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to endogenous gonadotropin-releasing hormone (GnRH) produced by hypothalamic neurons in the arcuate nucleus. It binds to GnRH receptors (GnRHR), a Gq/11-coupled GPCR on pituitary gonadotroph cells, activating phospholipase C, generating IP3 and DAG, and raising intracellular calcium to trigger the release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
The critical pharmacological principle of gonadorelin is that its biological effect depends entirely on the pattern of administration. Pulsatile administration (mimicking the hypothalamic GnRH pulse generator, which fires approximately every 60-90 minutes) maintains gonadotroph sensitivity and produces physiological LH/FSH release. This pulsatile pattern is essential because GnRHR undergoes rapid desensitization and internalization upon continuous stimulation. Continuous or high-frequency GnRH exposure causes receptor downregulation, depleting the gonadotroph cell surface of functional receptors, and paradoxically suppresses LH and FSH — the principle exploited by GnRH agonist depot formulations (leuprolide, goserelin) used for chemical castration in prostate cancer and endometriosis.
In the context of testosterone replacement therapy (TRT), gonadorelin is used to maintain intratesticular testosterone (ITT) and spermatogenesis, which would otherwise be suppressed by exogenous testosterone through negative feedback. Exogenous testosterone signals the hypothalamus and pituitary to reduce GnRH, LH, and FSH secretion, causing the testes to atrophy and sperm production to cease. By providing pulsatile GnRH stimulation, gonadorelin keeps the LH signal active, maintaining Leydig cell testosterone production and Sertoli cell-supported spermatogenesis. This has made gonadorelin an increasingly popular alternative to HCG for fertility preservation during TRT, especially since the FDA's reclassification of HCG as a biologic restricted compounding availability.
Regulatory Status
FDA approved (Factrel) as a diagnostic agent. Off-label use for TRT support and fertility through compounding pharmacies. Being used as HCG alternative since HCG availability became restricted.
Risks & Safety
Common
headache, facial flushing, redness at the injection site, brief lightheadedness.
Serious
if taken continuously instead of in pulses, it can shut down hormone production (the opposite of what you want).
Rare
allergic reactions, severe hot flashes if the body stops responding to it.
Compare Gonadorelin With
Research Papers
30Published: March 23, 2026
AI Summary
Menstrual suppression reduces bleeding risk in patients with blood cancers. The review compares GnRH agonists, progestins, and hormonal contraception and outlines how to choose based on efficacy, thrombosis risk, and patient needs.
Published: January 22, 2025
AI Summary
Secretoneurin stimulates LH release and is linked to GnRH around ovulation in mice. The work clarifies how this peptide fits into the periovulatory hormone cascade.
Published: February 25, 2026
AI Summary
GnRH neurons responded differently to GABA input with development and prenatal androgen exposure in a PCOS-like mouse model. These changes may contribute to the fertility problems seen in PCOS.
Published: December 12, 2025
AI Summary
Men with opioid dependence had very high rates of sexual dysfunction and elevated GnRH, but hormones did not independently predict function. Psychosocial and demographic factors mattered more than hormone levels.
Published: January 17, 2026
AI Summary
POLR3B mutations cause a rare form of hypogonadotropic hypogonadism as part of 4H leukodystrophy. Identifying the genetic cause clarified the diagnosis and associated conditions in the reported case.
Published: January 24, 2026
AI Summary
Triptorelin microspheres matched standard triptorelin for suppressing estrogen and relieving pain in endometriosis, with similar safety. Menstruation returned sooner after stopping the microsphere formulation.
Published: January 13, 2026
AI Summary
Long COVID patients showed delayed LH and FSH responses to GnRH, suggesting hypothalamic dysfunction rather than permanent pituitary damage. Endocrine testing should guide hormone replacement decisions.
Published: February 4, 2026
AI Summary
Immunizing macaques against GnRH-II did not stop ovulation despite high antibody titers. GnRH vaccines may not be effective contraceptives, though drugs that target GnRH-II could still be useful.
Published: January 6, 2025
AI Summary
Researchers tested whether BMI affects basal LH in girls with early puberty. The work explores how body weight may influence gonadotropin secretion in ICPP.
Published: January 4, 2025
AI Summary
Fertility preservation for young breast cancer patients includes embryo/oocyte freezing, ovarian tissue cryopreservation, and GnRH agonists. The review covers guidelines, options, and pregnancy safety after treatment.
Published: December 2, 2026
AI Summary
Extending progesterone-based ovulation sync from 7 to 11–14 days did not change conception rates in Japanese Black cows. Longer protocols improved estrus expression; breeding at detected estrus is recommended.
Published: December 31, 2025
AI Summary
GLP-1 agonists may improve fertility in obese men and women with PCOS by acting on GnRH and Kiss neurons and improving hormones. Use before pregnancy requires careful contraception and discontinuation planning.
Published: January 8, 2026
AI Summary
GnRH at the start of estrus sync improved ovulation timing in mares but did not raise pregnancy rates. The work supports GnRH for tighter synchronization during the spring transition.
Published: March 31, 2026
AI Summary
Replacing estradiol with gonadorelin or buserelin in ovulation sync protocols lowered fertility in Bos indicus cows compared with estradiol-based protocols. Estradiol-free protocols need further optimization.
Published: January 10, 2026
AI Summary
A novel SEMA3A exon deletion was identified in a Kallmann syndrome patient. The work explores how this variant disrupts reproductive and olfactory development.
Published: January 1, 2026
AI Summary
GnRH-like peptides were identified in the spotted Babylon snail, with expression in ganglia and ovaries. The work lays groundwork for understanding neuroendocrine control of reproduction in this species.
Published: March 4, 2026
AI Summary
A new LHRH-targeting peptide (LHRH-III') delivered chemotherapy to breast tumors with better uptake and less liver accumulation than older peptides. The conjugate showed strong antitumor activity in preclinical models.
Published: January 22, 2026
AI Summary
In a TAI program with sex-sorted semen, insemination at 18 h matched conventional semen results best; 22 h performed worse. Cows responding to the first GnRH had higher conception rates.
Published: February 8, 2026
AI Summary
An organ-on-chip model of the hypothalamic-pituitary axis showed that phoenixin-20 raised GnRH and modulated kisspeptin, NKB, and LH/FSH. The system offers a tool for studying reproductive neuroendocrinology.
Published: January 7, 2026
AI Summary
Pregnancy outcomes were compared across ovulation induction protocols in IVF cycles with donor sperm. The work informs protocol choice for these patients.
Published: February 9, 2026
AI Summary
Neoadjuvant endocrine therapy with palbociclib and chemotherapy was tailored by Ki67 in stage II–III breast cancer. The phase II study explored patient selection and second-line options for non-responders.
Published: January 5, 2026
AI Summary
MED12 wild-type fibroids had higher CDK8 activity and responded better to GnRH agonist treatment. CDK8 inhibitors slowed growth of wild-type fibroid cells in culture.
Published: January 4, 2026
AI Summary
Prescribing patterns for menstrual suppression and uterine bleeding in hematologic malignancy were reviewed to develop institutional guidelines. The work supports a standardized approach for these patients.
Published: January 4, 2026
AI Summary
DMPA and NET-EN affected the hypothalamic-pituitary-gonadal axis differently; DMPA raised FSH while NET-EN lowered it. These differences may explain why DMPA users had more amenorrhea.
Published: December 16, 2025
AI Summary
Progesterone on the hCG trigger day and the progesterone-to-basal ratio were analyzed for their effect on pregnancy in GnRH antagonist IVF cycles. The work informs trigger and transfer timing.
Published: November 30, 2026
AI Summary
Progestin-primed ovarian stimulation matched GnRH antagonist protocols for oocyte yield in fertility preservation, with much lower drug cost. PPOS is a practical, cost-effective option.
Published: December 22, 2025
AI Summary
Broiler selection changed expression of GnRH, growth hormone, and other neuroendocrine genes during embryonic development. The work shows how breeding has altered hypothalamic-pituitary regulation in poultry.
Published: December 10, 2025
AI Summary
GnRHa and hCG triggers gave similar pregnancy rates in PCOS IVF patients, with GnRHa potentially lowering OHSS risk. Trigger choice should be individualized by OHSS risk and patient characteristics.
Published: December 10, 2025
AI Summary
The review compares hCG, GnRHa, dual trigger, and kisspeptin for final oocyte maturation in IVF. GnRHa reduces OHSS risk but needs tailored luteal support; trigger choice should be patient-specific.
Published: December 8, 2025
AI Summary
LHRH/GnRH receptor-targeted therapies improved tumor uptake and reduced toxicity in ovarian cancer models. The review covers peptide-drug conjugates and nanosystems as targeted treatment options.
Frequently Asked Questions
What is Gonadorelin?
A lab-made copy of the hormone your brain naturally releases to tell your body to make reproductive hormones. When given in short pulses (not continuously), it signals the pituitary gland to release hormones that keep the testes working. Used for fertility treatment, diagnosing hormone problems, and keeping testicular function and sperm production going during testosterone therapy.
What is Gonadorelin used for?
A lab-made copy of the hormone your brain naturally releases to tell your body to make reproductive hormones. When given in short pulses (not continuously), it signals the pituitary gland to release hormones that keep the testes working. Used for fertility treatment, diagnosing hormone problems, and keeping testicular function and sperm production going during testosterone therapy.
What is the dosage for Gonadorelin?
Fertility/TRT support: 100-200 mcg subcutaneous two or three times weekly. Diagnostic (GnRH stimulation test): 100 mcg IV bolus. Critical: must be administered in a pulsatile pattern — continuous dosing paradoxically suppresses gonadotropins.
What are the side effects of Gonadorelin?
Common: headache, facial flushing, redness at the injection site, brief lightheadedness. Serious: if taken continuously instead of in pulses, it can shut down hormone production (the opposite of what you want). Rare: allergic reactions, severe hot flashes if the body stops responding to it.
How does Gonadorelin work?
Gonadorelin is a synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to endogenous gonadotropin-releasing hormone (GnRH) produced by hypothalamic neurons in the arcuate nucleus. It binds to GnRH receptors (GnRHR), a Gq/11-coupled GPCR on pituitary gonadotroph cells, activating phospholipase C, generating IP3 and DAG, and raising intracellular calcium to trigger the release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The critical pharmacological principle of gonadorelin is that its biological effect depends entirely on the pattern of administration. Pulsatile administration (mimicking the hypothalamic GnRH pulse generator, which fires approximately every 60-90 minutes) maintains gonadotroph sensitivity and produces physiological LH/FSH release. This pulsatile pattern is essential because GnRHR undergoes rapid desensitization and internalization upon continuous stimulation. Continuous or high-frequency GnRH exposure causes receptor downregulation, depleting the gonadotroph cell surface of functional receptors, and paradoxically suppresses LH and FSH — the principle exploited by GnRH agonist depot formulations (leuprolide, goserelin) used for chemical castration in prostate cancer and endometriosis. In the context of testosterone replacement therapy (TRT), gonadorelin is used to maintain intratesticular testosterone (ITT) and spermatogenesis, which would otherwise be suppressed by exogenous testosterone through negative feedback. Exogenous testosterone signals the hypothalamus and pituitary to reduce GnRH, LH, and FSH secretion, causing the testes to atrophy and sperm production to cease. By providing pulsatile GnRH stimulation, gonadorelin keeps the LH signal active, maintaining Leydig cell testosterone production and Sertoli cell-supported spermatogenesis. This has made gonadorelin an increasingly popular alternative to HCG for fertility preservation during TRT, especially since the FDA's reclassification of HCG as a biologic restricted compounding availability.
How is Gonadorelin administered?
Gonadorelin is administered via subcutaneous or intravenous injection.
What is the half-life of Gonadorelin?
The half-life of Gonadorelin is 2-4 minutes.
Is Gonadorelin legal?
FDA approved (Factrel) as a diagnostic agent. Off-label use for TRT support and fertility through compounding pharmacies. Being used as HCG alternative since HCG availability became restricted.
Related Peptides
ACE-031
An experimental drug that acts as a 'decoy' to intercept myostatin and other muscle-limiting signals before they reach your muscles. It produced rapid muscle gains in clinical trials without any exercise. However, development was halted because it also accidentally blocked signals needed to maintain healthy blood vessels, causing nosebleeds and visible broken blood vessels. A powerful proof-of-concept that myostatin blocking works, but too dangerous in its current form.
AICAR
A natural compound that activates your cells' energy sensor — the same pathway that turns on during exercise. Mimics the metabolic effects of endurance exercise at the cellular level, helping with fat burning, glucose uptake, and building more mitochondria. Banned by WADA as a metabolic modulator after detection in professional cycling.
Alprostadil
A medication that treats erectile dysfunction by relaxing the blood vessels in the penis, allowing blood to flow in and create an erection. Unlike pills that require arousal to work, this works directly at the injection or application site — you don't need to be in the mood. Available as an injection into the penis or as a small pellet inserted into the urethra.
BPC-157
A healing compound made from a protein found in stomach fluid. It's the most studied peptide for tissue repair, with research showing it helps heal tendons, ligaments, muscles, the gut, and other organs. It's stable enough to survive stomach acid, so you can take it either by injection under the skin or by mouth.